Development and validation of an LC-MS/MS assay for the quantitative analysis of alprazolam, α-hydroxyalprazolam and hydrocodone in dried blood spots

•Dried blood spot (DBS) analysis of alprazolam, α-hydroxyalprazolam, and hydrocodone.•Drug analysis of a 17-year-old forensic DBS sample.•First LC-MS/MS DBS method for the simultaneous analysis of alprazolam & hydrocodone.•LC-MS/MS DBS analysis cross-validated with LC-QTOF/MS whole blood analysi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of chromatography. B, Analytical technologies in the biomedical and life sciences Analytical technologies in the biomedical and life sciences, 2023-04, Vol.1220, p.123639-123639, Article 123639
Main Authors: Abarca, Radek, Gerona, Roy
Format: Article
Language:English
Subjects:
Alprazolam
Alprazolam in DBS
Chromatography, Liquid - methods
Dried blood spot analysis
Dried Blood Spot Testing - methods
Hydrocodone
Hydrocodone in DBS
LC-MS/MS
Reproducibility of Results
Tandem Mass Spectrometry - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Dried blood spot (DBS) analysis of alprazolam, α-hydroxyalprazolam, and hydrocodone.•Drug analysis of a 17-year-old forensic DBS sample.•First LC-MS/MS DBS method for the simultaneous analysis of alprazolam & hydrocodone.•LC-MS/MS DBS analysis cross-validated with LC-QTOF/MS whole blood analysis. Dried blood spot (DBS) has been used as an alternative matrix in drug testing. In forensic testing it offers enhanced stability of analytes and ease of storage that requires minimal space. This is compatible with long term archiving of large numbers of samples for future investigation. We employed liquid chromatography-tandem mass spectrometry (LC-MS/MS) to quantify alprazolam, α-hydroxyalprazolam, and hydrocodone in a DBS sample that has been stored for 17 years. We achieved linear dynamic ranges (0.1–50 ng/mL) that capture wide ranges of concentration of the analytes below and above their reported reference ranges, and limits of detection (0.05 ng/mL) of 40-100X lower than the lower limit of the analyte’s reference ranges. The method was validated according to FDA and CLSI guidelines and successfully confirmed and quantified alprazolam and α-hydroxyalprazolam in a forensic DBS sample.
ISSN:1570-0232
1873-376X
DOI:10.1016/j.jchromb.2023.123639